Vectorized Antibodies for In Vivo Expression by DNA and mRNA: an emerging new technology
- Category: Press Room
- Published on Thursday, 01 July 2021 09:29
- Hits: 2046
BARCELONA, Spain I July 1, 2021 I La Merie Publishing announced the release of its newest report about in vivo delivery of nucleic acid-encoded antibodies . The report “Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective” provides a landscape description and analysis of direct in vivo delivery of nucleic acid-encoded antibodies employing DNA and mRNA platform technologies from an industry perspective as of July 2021. In vivo gene-encoded antibody delivery is an elegant approach to address many of the limitations of conventional therapeutic antibodies. The three main approaches for antibody vectorization are:
- Adenoassociated virus (AAV) vector for delivery of DNA: AAV DNA;
- Synthetic plasmid DNA utilizing an electroporation device to enhance transfection efficiency after IM delivery: plasmid DNA;
- mRNA formulated in lipid nanoparticles (LNP): LNP mRNA.
The report brings you up-to-date with information about and analysis of
- Approaches of in vivo expression of therapeutic antibodies;
- Stakeholders in the field: technology and major pharmaceutical companies and investors;
- Gene therapy technologies for antibody vectorization: DNA, mRNA;
- Delivery technologies: adenoassociated virus (AAV) vector; electroporation; lipid nanoparticles (LNPs)
- Targets and therapeutic indications selected for development of vectorized antibodies;
- Preclinical and clinical experience with selected vectorized antibodies;
- Financing situation of technology companies and key investors in the field
- Partnering deals with financial terms;
- Business strategy: indications, development path, technology partnering, investment case;
- Major pharmaceutical companies: in-house technologies, R&D, collaborations.
Passive immunotherapy with conventional recombinant monoclonal antibodies has become a clinically and commercially extremely successful treatment modality. Breakthroughs in recombinant antibody technologies have resulted in the regulatory approval and commercialization of over 100 monoclonal antibodies (mAbs) to treat a variety of diseases. Sales of recombinant therapeutic antibodies in the year 2020 exceeded US$ 184 bln (+11% vs previous year).
However, there exist a number of limitations and challenges for passive immunotherapy, such as costly and time-consuming manufacturing, inconvenient administration protocols, a relatively short half leading to the need for repeated administration in case of chronic therapy. The blood-brain barrier (BBB) is a special concern for recombinant antibody therapy. The BBB prevents antibody entry to the central nervous system (CNS). Furthermore, antibodies do not enter the intracellular proteome. Systemically administered recombinant antibodies also have a potentialll for unspecific or toxic off-target effects.
Antibody vectorization intends to overcome such limitations of conventional passive immunotherapy. Each of the three different approaches (AAV DNA, plasmid DNA and mRNA) for in vivo expression of antibodies has its specific profile of advantages and disadvantages.
This report evaluates the industry landscape of antibody vectorization with optimized technologies for direct in vivo delivery of synthetic nucleic acid-encoded antibodies. The report is based on the identification and description of 26 companies with activities in the field of in vivo expressed therapeutic antibodies
What will you find in the report?
- Profiles of antibody vectorization technology companies active in the field;
- Description of major pharma’s/biotech’s role in the field (in-house R&D, partnering and investing);
- Comprehensive description and analysis of emerging vectorized antibodies;
- Pharmacologic profiles of selected vectorized antibodies;
- Characterization, profiling and state of antibody vectorization technologies;
- Target and indication selection for each antibody vectorization technology;
- Description and analysis of financing rounds (capital raised, investors);
- Economic terms of collaboration and licensing deals;
- Sources of financing.
The report Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspectivecan be acquired at La Merie Publishing’s online store: https://lamerie.com/report/vectorized-antibodies-for-in-vivo-expression-by-dna-and-mrna-a-landscape-analysis-of-stakeholders-technologies-targets-business-and-financing-from-an-industry-perspective/
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased the online store www.lamerie.com and at selected Resellers.
The focus of our products is directed towards therapeutic biologics, such as antibodies, proteins, peptides, vaccines and gene & cell therapy. La Merie pays special attention to biosimilar antibodies and proteins, antibody drug conjugates, bispecific antibodies, TCR & CAR engineered antibodies, mRNA vaccines & therapeutics, oncolytic viruses and immuno-oncology in general.
To leverage its expertise and knowledge accumulated in the in-house database, La Merie Publishing offers custom report preparation services for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest for our clients.
SOURCE: La Merie Publishing